



May 26, 2016

Kana Enomoto, Acting Administrator  
Substance Abuse and Mental Health Services Administration  
Department of Health and Human Services  
Attn: SAMHSA-0930-AA22  
5600 Fishers Lane, Room 13E21C  
Rockville, Maryland 20857

Dear Acting Administrator Enomoto:

On behalf of the American Academy of Family Physicians (AAFP), which represents 124,900 family physicians and medical students across the country, I am responding to the [proposed rule](#) "Medication Assisted Treatment for Opioid Use Disorders" which was published by the Substance Abuse and Mental Health Services Administration (SAMHSA) in the March 30, 2016 Federal Register.

The AAFP concurs with SAMHSA's interest in stimulating broader availability of high-quality medication-assisted therapy (MAT) and supports amending the highest cap on the treatment of addiction care with buprenorphine hydrochloride and naloxone hydrochloride to raise the limit to 200 patients from the current cap of 100 patients. In 2013, the AAFP [wrote](#) to the Drug Enforcement Administration (DEA) to call for amending the cap in primary care on the treatment of addiction care with buprenorphine hydrochloride and naloxone hydrochloride to raise the limit to 200 patients from the cap of 100 patients. We saw the 100-patient limit as an impediment to expanding opioid addiction treatment.

We appreciate SAMHSA's clarifying the five elements of a "qualified practice setting." As proposed, the qualified practice setting provision would allow willing and qualified family physicians who already have *Drug Addiction Treatment Act of 2000* (DATA 2000) waivers or those become waived to qualify for the 200 patient limit. However, we are concerned that the added reporting requirements in the proposed rule will dampen the interest of our members to begin or expand prescribing MAT to additional patients.

The 3-year limit set in the proposed rule on the expanded prescribing privilege with a requirement to recertify the waiver expansion request might have the unintended consequence of reducing the interest of physicians in expanding MAT. The AAFP would suggest that rather than an arbitrary 3-year term, SAMSHA could propose that the highest patient limit should be based on a periodic review of that practice and its outcome statistics.

The AAFP commends SAMSHA for this effort to increase the number of patients a waived physician can treat with MAT, but this proposed rule is just an incremental step. The proposed

[www.aafp.org](http://www.aafp.org)

---


<b>President</b> Wanda Filer, MD York, PA	<b>President-elect</b> John Meigs, Jr., MD Brent, AL	<b>Board Chair</b> Robert L. Wergin, MD Milford, NE	<b>Directors</b> Yushu "Jack" Chou, MD, <i>Baldwin Park, CA</i> Robert A. Lee, MD, <i>Johnston, IA</i> Michael Munger, MD, <i>Overland Park, KS</i> Mott Blair, IV, MD, <i>Wallace, NC</i> John Cullen, MD, <i>Valdez, AK</i> Lynne Lillie, MD, <i>Woodbury, MN</i>	John Bender, MD, <i>Fort Collins, CO</i> Gary LeRoy, MD, <i>Dayton, OH</i> Carl Olden, MD, <i>Yakima, WA</i> Marie-Elizabeth Ramas, MD, (New Physician Member), <i>Mount Shasta, CA</i> Richard Bruno, MD, (Resident Member), <i>Baltimore, MD</i> Tiffany Ho (Student Member), <i>Baltimore, MD</i>
<b>Speaker</b> Javette C. Orgain, MD Chicago, IL	<b>Vice Speaker</b> Alan Schwartzstein, MD Oregon, WI	<b>Executive Vice President</b> Douglas E. Henley, MD Leawood, KS		

Acting Administrator Enomoto  
Page 2 of 2  
May 26, 2016

rule does not address the many reasons cited by our members as to why they are not prescribing MAT to the fullest extent of their current waiver. We have heard concerns about governmental and third party reimbursement for the additional reporting, documentation, counseling and other requirements to prescribe MAT, concerns about the on-site DEA inspections, as well as the challenges of access to the counseling services in many rural and underserved communities necessary to meet the requirements of MAT prescribing.

Thank you for this opportunity to comment on this important public health initiative. If you have questions about these comments, please contact AAFP Senior Government Relations Representative, [Teresa Baker](#) at 202-232-9033.

Sincerely,

A handwritten signature in black ink that reads "Robert Wergin MD". The signature is cursive and includes the letters "MD" at the end.

Robert Wergin, MD, FAAFP  
Board Chair

cc: JinheeLee, PharmD [email: [WaiverRegulations@samhsa.hhs.gov](mailto:WaiverRegulations@samhsa.hhs.gov)]